Developmental Evaluation of Infants Who Have Received Tadalafil in Utero for Fetal Growth Restriction
To assess the long-term effects of tadalafil, a therapeutic agent for fetal growth restriction (FGR), we evaluated the developmental progress of 1.5-year-old infants whose mothers had taken tadalafil during pregnancy. Twenty-four infants were assessed. We evaluated infant body weight, height, and he...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-05-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/9/5/1448 |
| _version_ | 1797568174868135936 |
|---|---|
| author | Shintaro Maki Ineko Kato Naosuke Enomoto Sho Takakura Masafumi Nii Kayo Tanaka Hiroaki Tanaka Shinsuke Hori Kana Matsuda Yukito Ueda Hirofumi Sawada Masahiro Hirayama Akihiro Sudo Tomoaki Ikeda |
| author_facet | Shintaro Maki Ineko Kato Naosuke Enomoto Sho Takakura Masafumi Nii Kayo Tanaka Hiroaki Tanaka Shinsuke Hori Kana Matsuda Yukito Ueda Hirofumi Sawada Masahiro Hirayama Akihiro Sudo Tomoaki Ikeda |
| author_sort | Shintaro Maki |
| collection | DOAJ |
| description | To assess the long-term effects of tadalafil, a therapeutic agent for fetal growth restriction (FGR), we evaluated the developmental progress of 1.5-year-old infants whose mothers had taken tadalafil during pregnancy. Twenty-four infants were assessed. We evaluated infant body weight, height, and head circumference, and performed the Kyoto Scale of Psychological Development (KSPD) test, a standardized developmental assessment covering Postural–Motor (P–M), Cognitive–Adaptive (C–A), and Language-Social (L–S) functions. The sum score was converted to a developmental quotient (DQ). The mean gestational week of the included cases was 36.1 (29–39) weeks, and the mean birth weight was 1841 (874–2646) g. Twenty-one and 20 out of the 24 cases, respectively, attained body weight and height similar to those of age-matched normal infants (within the 3rd percentile); all cases caught up in head circumference. KSPD was performed for 18 cases at 1.5 years of corrected age. The mean DQ scores were 87 (in total): 82 in P–M, 90 in C–A, and 88 in L–S. The total DQ score in one case (5.6%) was less than 70, and ranged from 70 to 85 in five cases (27.7%), and was more than 85 in 11 cases (61.1%). The growth and development of infants born of tadalafil-treated mothers seem to show good progress at a corrected age of 1.5 years. |
| first_indexed | 2024-03-10T19:52:42Z |
| format | Article |
| id | doaj.art-8b94335cdc3247c4b950f7fb83f491d7 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T19:52:42Z |
| publishDate | 2020-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-8b94335cdc3247c4b950f7fb83f491d72023-11-20T00:16:34ZengMDPI AGJournal of Clinical Medicine2077-03832020-05-0195144810.3390/jcm9051448Developmental Evaluation of Infants Who Have Received Tadalafil in Utero for Fetal Growth RestrictionShintaro Maki0Ineko Kato1Naosuke Enomoto2Sho Takakura3Masafumi Nii4Kayo Tanaka5Hiroaki Tanaka6Shinsuke Hori7Kana Matsuda8Yukito Ueda9Hirofumi Sawada10Masahiro Hirayama11Akihiro Sudo12Tomoaki Ikeda13Department of Obstetrics and Gynecology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie 5148507, JapanDepartment of Obstetrics and Gynecology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie 5148507, JapanDepartment of Obstetrics and Gynecology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie 5148507, JapanDepartment of Obstetrics and Gynecology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie 5148507, JapanDepartment of Obstetrics and Gynecology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie 5148507, JapanDepartment of Obstetrics and Gynecology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie 5148507, JapanDepartment of Obstetrics and Gynecology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie 5148507, JapanDepartment of Rehabilitation, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie 5148507, JapanDepartment of Rehabilitation, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie 5148507, JapanDepartment of Rehabilitation, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie 5148507, JapanDepartment of Pediatrics, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie 5148507, JapanDepartment of Pediatrics, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie 5148507, JapanDepartment of Rehabilitation, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie 5148507, JapanDepartment of Obstetrics and Gynecology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie 5148507, JapanTo assess the long-term effects of tadalafil, a therapeutic agent for fetal growth restriction (FGR), we evaluated the developmental progress of 1.5-year-old infants whose mothers had taken tadalafil during pregnancy. Twenty-four infants were assessed. We evaluated infant body weight, height, and head circumference, and performed the Kyoto Scale of Psychological Development (KSPD) test, a standardized developmental assessment covering Postural–Motor (P–M), Cognitive–Adaptive (C–A), and Language-Social (L–S) functions. The sum score was converted to a developmental quotient (DQ). The mean gestational week of the included cases was 36.1 (29–39) weeks, and the mean birth weight was 1841 (874–2646) g. Twenty-one and 20 out of the 24 cases, respectively, attained body weight and height similar to those of age-matched normal infants (within the 3rd percentile); all cases caught up in head circumference. KSPD was performed for 18 cases at 1.5 years of corrected age. The mean DQ scores were 87 (in total): 82 in P–M, 90 in C–A, and 88 in L–S. The total DQ score in one case (5.6%) was less than 70, and ranged from 70 to 85 in five cases (27.7%), and was more than 85 in 11 cases (61.1%). The growth and development of infants born of tadalafil-treated mothers seem to show good progress at a corrected age of 1.5 years.https://www.mdpi.com/2077-0383/9/5/1448FGRPDE5 inhibitortadalafilKSPD |
| spellingShingle | Shintaro Maki Ineko Kato Naosuke Enomoto Sho Takakura Masafumi Nii Kayo Tanaka Hiroaki Tanaka Shinsuke Hori Kana Matsuda Yukito Ueda Hirofumi Sawada Masahiro Hirayama Akihiro Sudo Tomoaki Ikeda Developmental Evaluation of Infants Who Have Received Tadalafil in Utero for Fetal Growth Restriction Journal of Clinical Medicine FGR PDE5 inhibitor tadalafil KSPD |
| title | Developmental Evaluation of Infants Who Have Received Tadalafil in Utero for Fetal Growth Restriction |
| title_full | Developmental Evaluation of Infants Who Have Received Tadalafil in Utero for Fetal Growth Restriction |
| title_fullStr | Developmental Evaluation of Infants Who Have Received Tadalafil in Utero for Fetal Growth Restriction |
| title_full_unstemmed | Developmental Evaluation of Infants Who Have Received Tadalafil in Utero for Fetal Growth Restriction |
| title_short | Developmental Evaluation of Infants Who Have Received Tadalafil in Utero for Fetal Growth Restriction |
| title_sort | developmental evaluation of infants who have received tadalafil in utero for fetal growth restriction |
| topic | FGR PDE5 inhibitor tadalafil KSPD |
| url | https://www.mdpi.com/2077-0383/9/5/1448 |
| work_keys_str_mv | AT shintaromaki developmentalevaluationofinfantswhohavereceivedtadalafilinuteroforfetalgrowthrestriction AT inekokato developmentalevaluationofinfantswhohavereceivedtadalafilinuteroforfetalgrowthrestriction AT naosukeenomoto developmentalevaluationofinfantswhohavereceivedtadalafilinuteroforfetalgrowthrestriction AT shotakakura developmentalevaluationofinfantswhohavereceivedtadalafilinuteroforfetalgrowthrestriction AT masafuminii developmentalevaluationofinfantswhohavereceivedtadalafilinuteroforfetalgrowthrestriction AT kayotanaka developmentalevaluationofinfantswhohavereceivedtadalafilinuteroforfetalgrowthrestriction AT hiroakitanaka developmentalevaluationofinfantswhohavereceivedtadalafilinuteroforfetalgrowthrestriction AT shinsukehori developmentalevaluationofinfantswhohavereceivedtadalafilinuteroforfetalgrowthrestriction AT kanamatsuda developmentalevaluationofinfantswhohavereceivedtadalafilinuteroforfetalgrowthrestriction AT yukitoueda developmentalevaluationofinfantswhohavereceivedtadalafilinuteroforfetalgrowthrestriction AT hirofumisawada developmentalevaluationofinfantswhohavereceivedtadalafilinuteroforfetalgrowthrestriction AT masahirohirayama developmentalevaluationofinfantswhohavereceivedtadalafilinuteroforfetalgrowthrestriction AT akihirosudo developmentalevaluationofinfantswhohavereceivedtadalafilinuteroforfetalgrowthrestriction AT tomoakiikeda developmentalevaluationofinfantswhohavereceivedtadalafilinuteroforfetalgrowthrestriction |